Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4536126 | 1.00 | MAPK1 (0.43) | MAPK1MEN1KMT2AGPR88PDK1 | |
| SCHEMBL1720123 | 1.00 | MAPK1 (0.43) | MAPK1MEN1KMT2AGPR88PDK1 | |
| SCHEMBL4338097 | 0.86 | MAPK1 (0.45) | MAPK1GPR88OPRK1LMNAHTT | |
| SCHEMBL206627 | 0.85 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL1720295 | 0.85 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL1720296 | 0.85 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL20266799 | 0.84 | PDE2A (0.53) | LMNAHTT | |
| SCHEMBL18247937 | 0.84 | PDE2A (0.53) | LMNAHTT | |
| SCHEMBL8540917 | 0.83 | LMNA (0.49) | MAPK1MEN1KMT2AGPR88OPRK1 | |
| SCHEMBL8540915 | 0.83 | LMNA (0.49) | MAPK1MEN1KMT2AGPR88OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819708-B1 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-7648988-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-01-19 | — | — | US | disclosed |
| US-20080153833-A1 | Substituted pteridines for the treatment of inflammatory diseases | DOLLINGER HORST | 2008-06-26 | — | — | US | disclosed |
| EP-1819708-A2 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058868-A2 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | MAPK1 3964/4885MEN1 1763/4885KMT2A 2516/4885 |
| US-20080153833-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | MAPK1 3964/4885MEN1 1763/4885KMT2A 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.